Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Fasiuddin Arif Mohammed. et al. / International Journal of Biological & Pharmaceutical Research. 2012; 3(1): 145-153.
ABSTRACT
The objective of this research work was to formulate and evaluate the extended release tablets containing 200mg of
Carbamazepine. Different excipients were tested for their compatibility with Carbamazepine, which revealed that there is no
physical and chemical interaction occurred. Extended release tablets were formulated by Wet Granulation method incorporating
HPMC K4M, a hydrophilic polymer, Dicalcium phosphate (Anhydrous) as diluent, Povidone (K-30) as Binder, Colloidal
silicon dioxide (Aerosil-200) as Glidant, Hydrogenated Castor Oil (Boricin Pharma) and Talc as lubricants. Dissolution profiles
were studied in Purified water as dissolution medium (900ml). The drug release were estimated at 3, 6, 12 and 24 hours by
Ultra violet – Visible spectrophotometer (UV 1601, Shimadzu), at 284 nm. The influence of variables like polymer type, drug:
polymer ratio on Carbamazepine profile release was studied. The release mechanisms of Carbamazepine extended release
tablets were evaluated. The thickness, hardness, friability, weight variation and drug content of the formulated extended release
tablets were evaluated. Based on the evaluation results, T9 (10% Methocel K4M) formulation was selected as the best
formulation, reproducibility trials were taken and the results were found to be satisfactory.
Key Words: Carbamazepine, Hydroxy Propyl Methyl Cellulose (HPMC K4M), Wet Granulation method, Extended release
drug delivery and Evaluation.
INTRODUCTION
Oral administration of drugs has been the most popularity of the oral route is attributed to patient
common and preferred route for delivery of most acceptance, ease of administration, accurate dosing, cost-
therapeutic agents. It remains the preferred route of effective manufacturing methods, and generally improved
administration investigated in the discovery and shelf-life of the product. For many drugs and therapeutic
development of new drug candidates and formulations. The indications, conventional multiple dosing of immediate
release formulations provides satisfactory clinical
Corresponding Author performance with an appropriate balance of efficacy and
safety. The rationale for development of an extended-
Fasiuddin Arif Mohammed release formulation of a drug is to enhance its therapeutic
Email: md.arif150@gmail.com benefits, minimizing its side effects while improving the
management of the diseased condition (Lloyd NS et al.,
1999).
146
Fasiuddin Arif Mohammed. et al. / International Journal of Biological & Pharmaceutical Research. 2012; 3(1): 145-153.
Carbamazepine is an anti convulsant and specific 2. DRY MIXING :Load the materials of stage-1 into
analgesic for trigeminal neuralgia that reduces planetary mixer and mix for 20 mins at slow speed.
polysynaptic responses and blocks post titanic potentiation.
Carbamazepine is effective in partial and generalized
convulsions and in mixed types. It is not effective in petit– 3. BINDERPREPARATION :Dissolve Povidone (K-
mal seizures. It reduces (or) abolishes pain in trigeminal 30) in a (1:1) mixture of Isopropyl Alcoholand
neuralgia and glosso pharyngeal neuralgia. Carbamazepine Methylene chloride.
extended release tablets are used to treat episodes of mania
(or) mixed episodes i.e., symptoms of mania and 4. GRANULATION:Add slowly binder solution of
depression that happen at the same time, in patients with stage – 3 to stage – 2 and mix for 5mins at slow speed.
bipolar disorder. It works by reducing abnormal excitement After complete addition of binder solution, mix until
in the brain (Gonzalez, Frank J et al., 2006; Bertilsson L et to get granules.
al., 1978).
The extended release drug products designed to 5. DRYING :Load the wet granules of stage – 4 into
reduce the frequency of dosing by modifying the rate of Tray drier, dry untill the moisture content of granules
drug absorption have been available for many years. Early is not more than 1.0%
modified-release products were often
intramuscular/subcutaneous injections of suspensions of 6. SIZING :Mill the dried granules of stage – 5 through
insoluble drug complexes, e.g. procaine penicillin, Multimill with 1.5 mm screen and sift through # 20
protamine zinc insulin, insulin zinc suspensions or mesh sieve. Retained granules mill through Multimill
injections of the drug in oil, e.g. Fluphenazine decanoate. and sift through # 20 mesh.
In conventional dosage forms, which include Capsules,
solutions, suspensions and tablets, the drug is released by
dissolution or diffusion. The resulting pattern of drug 7. LUBRICATION :Sift Colloidal silicon dioxide,
concentration in plasma can vary widely and may cause Hydrogenated castor oil (Boricin pharma) and talc
inconsistent and undesired clinical effects. The high peak through # 40 mesh, Load the granules of stage – 6 and
blood concentration reached soon after administration may lubricants into Octogonal blender. Mix for 3 minutes
result in adverse effects. With Controlled release products at slow speed.
the precise rate, extent or timing of drug entry into the
blood stream is predetermined or achieved with an integral 8. COMPRESSION :Compress the lubricated blend in a
drug – specific composition, structure or mechanism cadmach Compression machine with 9.5mm flat
(Collett J et al., 1988; Alderman DA et.al., 2002). punches with break line on one surface.
600C/80%RH) in stability chamber (Newtronic walkin to 500/ 750 and 1250 taps in tapped density tester (Electro
Humidity chamber, India).The study is carried out in open Lab USP II) the difference between two tabs should be less
and closed glass vials for a period of a month. The than 2%. The percentage of compressibility Index is
samples were withdrawn at intervals of 7, 15 and 30 days calculated by using formula (James L et al., 1985;
and characteristic like colour change, water content and Carri.R.L et al., 1965)
related substances was recorded. Finally the compatible
mixtures were selected for formulation (Kumar et al., CI=Vo-Vi/V*100
2010).
Where, Vo : Untapped density
Evaluation of granules Vi: Tapped density
DENSITY (g/ml)
Granule density, True Density, Bulk density may HAUSNER’S RATIO
influence compressibility, tablet porosity, flow property, It is measurement of frictional resistance of the
dissolution and other properties. Higher compression load drug. The Ideal range should be 1.2 -1.5. It was determined
is required in case of dense and hard granules which in turn by the ratio of tapped density to bulk density.
increase the tablet disintegration and drug dissolution time.
Density is usually determined by Pycnometer. Hausner’s Ratio = Vo/Vi
Bulk density Where, Vo : Untapped density
Procedure Vi : Tapped density
Weighed quantity of Carbamazepine granules was
transferred into a 50 ml measuring cylinder without ANGLE OF REPOSE
tapping. During transfer the volume occupied by granules Angle of Repose (Ф) is the maximum angle
was measured. Bulk density was measured by using between the surface of a pile of powder and horizontal
formula. plane. It is usually determined by fixed funnel method and
is the measure the flowability of powder /granules.
Pi = m/Vo
Where, Procedure
m : Mass of the blend Carbamazepine granules were passed through a
Vo: Untapped Volume funnel kept at a height of 2 cm from the base. The granules
were passed till it forms heap and touches the tip of the
Tapped Density funnel. The radius was measured and angle of repose was
Procedure calculated by using the formula.
Weighed quantity of Carbamazepine granules was Ф = tan –1(h/r) (or) Ф = tan –1(height /0.5 Base)
taken into a graduated cylinder, volume occupied by Where,
granules was noted down. Then cylinder was subjected to h : Height of the heap of pile
500/ 750 and 1250 taps in tapped density tester (Electro r : Radius of base of pile
Lab USP II) According to USP , the blend was subjected
for 500 taps the % Volume variation was calculated by WATER CONTENT
following formula. Water content (By KF)
Determine the water content of the sample by
Where, Pt = m/Vi using suitable Karl Fischer titrator. Transfer about 200ml
of the powdered tablet into the titration vessel and titer the
solution. Calculate the water content of the test sample by
m: Mass of the blend using the following equation.
Vi : Tapped Volume
Volume of K.F.Reagent X K.F Factor
COMPRESSIBILITY INDEX: (CI) Water content (%) = -------------------------------------X100
Compressibility is the ability of powder to Weight of the sample in mg
decrease in volume under pressure. Compressibility is a
measure that obtained from density determination. EVALUATION OF TABLETS
Weight variation test Repeat the above procedure for further 9 tablets
Ten tablets were selected randomly from each batch and calculates the content of Carbamazepine in percentage
and weighed individually to check for weight variation. A with respect to label claim and finds the average value for
little weight variation is allowed by U.S pharmacopeia. the 10 tablets tested. Calculate the limit for uniformity of
The following % weight variation is allowed (Ikinci G et content.
al., 1999; Vidyadhara S et al., 2003). (Values are given in
Table 5) In vitro dissolution studies
Apparatus : Dissolution Apparatus 1 USP (basket)
CONTENT OF UNIFORMITY Speed : 100 rpm
Standard preparation Medium : water; 900ml
Weigh accurately about 0.1g of Carbamazepine Temperature : 37 0 c + 0.5 0c
WS in to a 50ml volumetric flask, add 30ml of methanol, Time : 3rd, 6th, 12th and 24th hours
shake and sonicate to dissolve the content, makeup the
volume with methanol. Filter the solution through Procedure
membrane filter. Pipette out 5 ml of the above solution in In-vitro dissolution testing of Carbamazepine
to a 100 ml volumetric flask and makeup the volume with extended release tablets was carried out by using IP/USP
methanol. Further, pipette out 5ml of the above solution in dissolution apparatus (basket type and apparatus-1) with
to a 50ml volumetric flask and makeup the volume with 900ml of Distilled water as dissolution medium, which is
methanol. maintained at 37±0.50C. The basket was rotated at a fixed
rpm of 100 at specified interval time, required volume of
Sample preparation sample (1ml) was pipetted or withdraws out and diluted to
Randomly select 10 tablets. Finally powder one 10ml in volumetric flask with Distilled water, then finally,
tablet and transfer quantitatively the powdered tablet into a the absorbance of the sample solution in each flask was
100ml volumetric flask. Add 70ml of methanol shake by measured at 284 nm against Distilled water used as blank.
mechanical means for 60 minutes; sonicate for 15 minutes
and makeup the volume with methanol. Allow to stand for An amount of drug release and % drug release was
10 to 15 minutes, and then filter the portion of the calculated by using below formula:
supernatant solution through a membrane filter. Pipette out i) Amount of drug release =
5 ml of the above solution into a 100 ml volumetric flask Concentration (µg/ml) × Dilution factor (ml) × Bath volume (ml)
and makeup the volume with methanol. Further, pipette out 1000
ii) % Drug release = Amount of drug release × 100
5 ml of the above solution into a 50 ml volumetric flask Labelled claim
and make up the volume with methanol.
149
Fasiuddin Arif Mohammed. et al. / International Journal of Biological & Pharmaceutical Research. 2012; 3(1): 145-153.
Quantity/Tablet (mg)
Ingredients T-1 T-2 T-3 T-4 T-5 T-6 T-7 T-8 T-9 T-10 T-11 T-12
Carbamazepine 201.59 201.59 201.59 201.59 201.59 201.59 201.59 201.59 201.59 201.59 201.59 201.59
Hydroxy Propyl
Methyl Cellulose 97.50 89.38 81.25 73.12 65.00 56.87 48.75 40.63 32.500 32.50 32.50 32.50
(Methocel K4M)
Hydroxy Propyl
Methyl Cellulose _ _ _ _ _ _ _ _ 6.250 _ _ _
(HPMC 5CPs)
Dibasic calcium
phosphate 3.91 12.03 20.16 28.29 36.41 44.54 52.66 60.78 52.660 68.91 68.91 68.91
(Anhydrous)
Povidone (K-30) 10.00 10.00 10.00 10.00 10.000 10.00 10.00 10.00 10.00 10.000 10.000 10.000
Isopropyl Alcohol q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s
Methylene chloride q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s
Hydrogenated
castor oil 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.000 5.000 5.000
(Boricin pharma)
Colloidal silicon
dioxide 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.000 2.000 2.000
(Aerosil – 200)
Talc 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.000 5.000 5.000
Average Weight 325.00 325.00 325.00 325.00 325.00 325.00 325.00 325.00 325.00 325.00 325.00 325.00
Conditions
Initial
400C/75%RH 600C/90%RH
S.No Drug+ Excipients Parameter value of
2 4 2 4
parameters
Week Week Week week
Any colour No colour No colour No colour No colour No colour
1 Carbamazepine
change change change change change change
Carbamazepine + Dibasic
Any colour No colour No colour No colour No colour No colour
2 calcium phosphate
change change change change change change
(Anhydrous)
Carbamazepine+ HPMC Any colour No colour No colour No colour No colour No colour
3
K4M change change change change change change
Carbamazepine+ HPMC 5 Any colour No colour No colour No colour No colour No colour
4
CPs change change change change change change
Carbamazepine+ Povidone Any colour No colour No colour No colour No colour No colour
5
(K-30) change change change change change change
Carbamazepine + Iso
Any colour No colour No colour No colour No colour No colour
6 propyl alcohol &
change change change change change change
methylene chloride
Carbamazepine + colloidal
Any colour No colour No colour No colour No colour No colour
7 silicon dioxide (Aerosil-
change change change change change change
200)
Any colour No colour No colour No colour No colour No colour
8 carbamazepine+Talc
change change change change change change
Carbamazepine+
Any colour No colour No colour No colour No colour No colour
9 hydrogenated castor oil
change change change change change change
(Boricin pharma)
151
Fasiuddin Arif Mohammed. et al. / International Journal of Biological & Pharmaceutical Research. 2012; 3(1): 145-153.
Complies
Complies
Complies
Complies
Complies
Complies
Complies
Complies
Complies
Complies
Complies
uncoated
1 Description
extended
tablets with a
break line on
one surface.
Complies
Complies
Complies
Complies
Complies
Complies
Complies
Complies
Complies
Complies
Complies
Complies
Passes for
Identificati
2 carbamazepin
on test
e
321-329mg
Average (Taget
3 325.2 324.9 324.5 325.2 325.5 324.8 325.1 324.6 324.9 323.8 325.4 324.2
weight weight-
325mg)
Thickness
4 3.6-4.0mm 3.80 3.72 3.68 3.89 3.72 3.90 3.84 3.78 3.72 324.6 324.9 323.8
(mm)
Hardness 4.0-8.0 6
5 5 5 6 5 4 5 4 4 5 6 5
(kg/cm2) Kg/cm2
Friability Not more than
6 0.11 0.14 0.12 0.11 0.16 0.15 0.18 0.12 0.15 0.15 0.14
(%w/w) 1.0% 0.08
± 5% from -2.5 -2.5 -2.4 -1.5 -1.9 -1.7 -2.4 -3.1 -2.4 -1.7 -1.5 -2.6
Weight
7 the avearge to to to to + to to to to to to to to
Variation
weight +1.9 +2.1 +1.8 2.8 +2.4 +3.1 +1.8 +2.5 +1.9 +2.7 +2.2 +1.9
Content
8 85 to 115% 95% 98% 97% 98% 98% 99% 97% 96% 98% 98% 99% 98%
Uniformity
152
Fasiuddin Arif Mohammed. et al. / International Journal of Biological & Pharmaceutical Research. 2012; 3(1): 145-153.
Invtro
S.no Dissolution Specification T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12
(%)
1.
Between 10% 4.3 6.9 7.9 11. 12.1 14.3 15.1 17.5 19.8 28.2 25.9 29.5
3rd hour
to 35% % % % 0% % % % % % % % %
2. Between35% 15.8 16. 18. 20. 23.4 28.5 33.9 35.6 33.5 50.2 48.9 51.3
6th hour
to 65% % 5% 3% 9% % % % % % % % %
3. Between 65% 32.3 39. 43. 48. 53.9 60.5 63.9 68.0 79.9 78.7 73.1 75.6
12th hour
to 90% % 6% 5% 9% % % % % % % % %
4. 58.0 60. 67. 70. 78.1 83.4 96.2 95.6 86.9 93.0 95.4 96.5
24th hour NLT 75%
% 8% 5% 9% % % % % % % % %
Fig 1: Theoretical drug concentration profile following Fig 2. Comparative Release profile of Carbmazepine ER
multiple dosing of a drug as an immediate-release form tablet of Trial 10, Trial-11, Trial-12 with Market sample
every 8 hours and as an extended-release form once every
24 hours.
REFERENCES
Alderman DA et al. Review of cellulose ether in matrices for oral controlled release dosage forms. Indian Journal of
Pharmaceutical Science. 2002; 135-142.
Bertilsson L. Clinical pharmacokinetics of Carbamazepine. Clinical Pharmacokinetics. 1978; 3: 128-43.
Carri.RL. Classifying flow properties of solid chemical Engineer 1965: 69-72.
Cascino GD. Epilepsy: contemporary perspectives on evaluation and treatment. Mayo Clinic Proc. 1994; 69: 1199-1211.
Collett J, Moreton C. Modified release peroral dosage forms: In: Pharmaceutics. The science of dosage forms. Churchill
Livingstone: Edenberg. 1988: 289-305.
Free patents online. Controlled release solid dosage Carbamazepine formulations - United States Patent 6572889.
Gonzalez Frank J, Robert H. Drug Metabolism, In Laurence Brunton, John Lazo, Keith Parker (eds.). Goodman & Gilman's the
Pharmacological Basis of Therapeutics (11th ed. ed.), 2006.
Guidelines for the design and evaluation of prolonged release dosage forms. Ministry of Health and Welfare, Japan (March 11,
1988). Available at: URL http:// www.nihs.go.jp/drug/be-guide(e)/CR_new .pdf.2006.
Ifat Katzhendler, Reuven Azoury, Michael Friedman; Crystalline properties of Carbamazepine in sustained release hydrophilic
matrix tablets based on Hydroxy propyl methycellulose. Journal of controlled release. 1998; 54: 69-85.
Ikinci G et al. Formulation and in vitro/ in vivo investigation of Carbamazepine controlled – release matrix tablets. Pharmazie.
1999; 54(2): 139-41.
James L. Ford, Michael H. Rubinstein and John E. Hogan. Formulation of sustained release promethazine hydrochloride tablets
using hydroxylpropylmethyl cellulose matrices, International Journal of Pharmaceutics. 1985; 24(2-3): 327-338.
Jerome Engel. A Proposed Diagnostic Scheme for People with Epileptic Seizures and With Epilepsy: Report of the Ilae Task
Force on Classification and Terminology. ILAE. Retrieved on 2006-07-18.
Kuksala et al. Formulation and in vitro, in vivo evaluation of extended release matrix tablets of zidovudine: influence of
combination of hydrophilic and hydrophobic matrix formers. AAPS PharmSci Tech. 2006; 7(1): E1.
Kumar et al, chemical stability studies of bioadhesive topical gel. Int J Pharm Pharm Sci. 2010; 3(1): 101-104.
Lloyd NS. Oral extended – release products. Aust Prescr. 1999; 22: 88-90.
Miller AD, Krauss GL, Hamzeh FM. Improved CNS tolerability following conversion from immediate- to extended-release
Carbamazepine. Acta Neurologica Scandinavia. 2004; 109(6): 374 – 377.
Owen RT. Extended – release Carbamazepine for acute bipolar mania; A Review. Drugs of Today. 2006; 42(5); 283.
Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on
Classification and Terminology of the International League against Epilepsy. Epilepsia. 1981; 22 (4): 489–501.
Rowe RC, Sheskey PJ, Weller PJ. Handbook of pharmaceutical excipients. 4th ed. London: Pharmaceutical Press; 2003,
Raymond C Rowe, Paul J Sheskey and Sian C Owen; Handbook of Pharmaceutical excipients.
Vidyadhara S. Formulation and evaluation of controlled release matrix tablets of diltiazem hydrochloride. Int J Pharm Exci.
2003; 83-6.